These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26440382)

  • 1. Inhibition profiles of mono- and polyvalent FimH antagonists against 10 different Escherichia coli strains.
    Chalopin T; Brissonnet Y; Sivignon A; Deniaud D; Cremet L; Barnich N; Bouckaert J; Gouin SG
    Org Biomol Chem; 2015 Dec; 13(46):11369-75. PubMed ID: 26440382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease.
    Sivignon A; Yan X; Alvarez Dorta D; Bonnet R; Bouckaert J; Fleury E; Bernard J; Gouin SG; Darfeuille-Michaud A; Barnich N
    mBio; 2015 Nov; 6(6):e01298-15. PubMed ID: 26578673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut.
    Alvarez Dorta D; Sivignon A; Chalopin T; Dumych TI; Roos G; Bilyy RO; Deniaud D; Krammer EM; de Ruyck J; Lensink MF; Bouckaert J; Barnich N; Gouin SG
    Chembiochem; 2016 May; 17(10):936-52. PubMed ID: 26946458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an aggregation assay to screen FimH antagonists.
    Abgottspon D; Rölli G; Hosch L; Steinhuber A; Jiang X; Schwardt O; Cutting B; Smiesko M; Jenal U; Ernst B; Trampuz A
    J Microbiol Methods; 2010 Sep; 82(3):249-55. PubMed ID: 20620174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against FimH-Dominated Uropathogenic Escherichia coli: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from Vaccinium macrocarpon.
    Rafsanjany N; Senker J; Brandt S; Dobrindt U; Hensel A
    J Agric Food Chem; 2015 Oct; 63(40):8804-18. PubMed ID: 26330108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK; Cusumano ZT; Janetka JW
    Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential stability and trade-off effects of pathoadaptive mutations in the Escherichia coli FimH adhesin.
    Weissman SJ; Beskhlebnaya V; Chesnokova V; Chattopadhyay S; Stamm WE; Hooton TM; Sokurenko EV
    Infect Immun; 2007 Jul; 75(7):3548-55. PubMed ID: 17502398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant?
    Mayer K; Eris D; Schwardt O; Sager CP; Rabbani S; Kleeb S; Ernst B
    J Med Chem; 2017 Jul; 60(13):5646-5662. PubMed ID: 28471659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn's disease patients.
    Brument S; Sivignon A; Dumych TI; Moreau N; Roos G; Guérardel Y; Chalopin T; Deniaud D; Bilyy RO; Darfeuille-Michaud A; Bouckaert J; Gouin SG
    J Med Chem; 2013 Jul; 56(13):5395-406. PubMed ID: 23795713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Mannopyranoside Therapeutics against Adherent-Invasive Escherichia coli Infections.
    Mousavifar L; Touaibia M; Roy R
    Acc Chem Res; 2018 Nov; 51(11):2937-2948. PubMed ID: 30289687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycan-functionalized diamond nanoparticles as potent E. coli anti-adhesives.
    Barras A; Martin FA; Bande O; Baumann JS; Ghigo JM; Boukherroub R; Beloin C; Siriwardena A; Szunerits S
    Nanoscale; 2013 Mar; 5(6):2307-16. PubMed ID: 23396565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biofilm formation by multidrug resistant Escherichia coli ST131 is dependent on type 1 fimbriae and assay conditions.
    Sarkar S; Vagenas D; Schembri MA; Totsika M
    Pathog Dis; 2016 Apr; 74(3):. PubMed ID: 26940589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
    Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn's disease.
    Chalopin T; Alvarez Dorta D; Sivignon A; Caudan M; Dumych TI; Bilyy RO; Deniaud D; Barnich N; Bouckaert J; Gouin SG
    Org Biomol Chem; 2016 Apr; 14(16):3913-25. PubMed ID: 27043998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiochemical Tuning of Potent Escherichia coli Anti-Adhesives by Microencapsulation and Methylene Homologation.
    Alvarez Dorta D; Chalopin T; Sivignon A; de Ruyck J; Dumych TI; Bilyy RO; Deniaud D; Barnich N; Bouckaert J; Gouin SG
    ChemMedChem; 2017 Jun; 12(12):986-998. PubMed ID: 28257558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes.
    Bouckaert J; Mackenzie J; de Paz JL; Chipwaza B; Choudhury D; Zavialov A; Mannerstedt K; Anderson J; Piérard D; Wyns L; Seeberger PH; Oscarson S; De Greve H; Knight SD
    Mol Microbiol; 2006 Sep; 61(6):1556-68. PubMed ID: 16930149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease.
    Sivignon A; Bouckaert J; Bernard J; Gouin SG; Barnich N
    Expert Opin Ther Targets; 2017 Sep; 21(9):837-847. PubMed ID: 28762293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.